Overview

Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

Status:
Enrolling by invitation

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

Summary

This Study is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/day and 6 mg/day in Patients with Acute Psychotic Episode of Schizophrenia.

Phase:

Phase 3

Details

Lead Sponsor:

Whanin Pharmaceutical Company

Treatments:

Cariprazine